Published in Core Evid on March 31, 2007
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26
HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (1996) 26.19
Identification of a major co-receptor for primary isolates of HIV-1. Nature (1996) 23.81
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (1996) 20.59
Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell (1996) 17.81
Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (1996) 15.91
The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science (1988) 11.05
Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med (2002) 9.70
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother (2005) 7.42
AIDS epidemic update: December 1999. AIDS Anal Afr (2000) 5.60
Reversal of integration and DNA splicing mediated by integrase of human immunodeficiency virus. Science (1992) 4.97
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med (2005) 4.83
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med (2003) 4.19
The prevalence of antiretroviral drug resistance in the United States. AIDS (2004) 3.90
The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses (2004) 3.75
Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet (2004) 3.59
Pathogenesis of infection with human immunodeficiency virus. N Engl J Med (1987) 3.45
A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. J Virol (1995) 3.11
The HIV-1 protease as a therapeutic target for AIDS. AIDS Res Hum Retroviruses (1992) 2.69
The entry of entry inhibitors: a fusion of science and medicine. Proc Natl Acad Sci U S A (2003) 2.43
Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis (2005) 2.42
Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J Virol (2005) 2.25
Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS (2002) 2.21
Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis (2005) 2.07
Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS (2002) 1.99
3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med (2000) 1.88
Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS (2002) 1.87
Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos (2005) 1.86
HIV-1 coreceptor usage, transmission, and disease progression. Curr HIV Res (2003) 1.71
Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven. J Antimicrob Chemother (2005) 1.67
Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. J Infect Dis (1999) 1.61
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). HIV Med (2005) 1.60
CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antivir Chem Chemother (2005) 1.54
A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J Infect Dis (2003) 1.51
The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS. Prog Med Chem (2005) 1.41
Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis (2005) 1.39
Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. J Infect Dis (2004) 1.31
A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc. Clin Pharmacol Ther (2005) 1.27
Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy. AIDS (2000) 1.13
Rates of transmission of antiretroviral drug resistant strains of HIV-1. J Clin Virol (2003) 1.12
Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression. J Infect Dis (2002) 1.05
HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort. Antivir Ther (2000) 1.01
Sch-351125 and Sch-350634. Schering-Plough. Curr Opin Investig Drugs (2002) 0.94
The HIV entry inhibitors revisited. Curr Med Chem (2006) 0.79
Exubera(®) (inhaled insulin): an evidence-based review of its effectiveness in the management of diabetes. Core Evid (2005) 0.78
Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. Core Evid (2008) 0.78
Eltrombopag: the emerging evidence of its therapeutic value in thrombocytopenia. Core Evid (2006) 0.76
Lumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis. Core Evid (2007) 0.75